This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!
Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Advanced
User Guide

Save citation to file

Add to Collections

Name must be less than 100 characters
Unable to load your collection due to an error
Please try again

Add to My Bibliography

Unable to load your delegates due to an error
Please try again

Your saved search

Test search terms
Would you like email updates of new search results?
Saved Search Alert Radio Buttons
()

Create a file for external citation management software

Your RSS Feed

Review
. 2013 May 16:6:36.
doi: 10.1186/1756-8722-6-36.

Novel agents for chronic lymphocytic leukemia

Mei Wu  1 , Akintunde Akinleye, Xiongpeng Zhu
Affiliations

Affiliation

  • 1 Department of Hematology, First Hospital of Quanzhou affiliated to Fujian Medical University, Quanzhou, 362000, China.
Review

Novel agents for chronic lymphocytic leukemia

Mei Wu et al. J Hematol Oncol. .
. 2013 May 16:6:36.
doi: 10.1186/1756-8722-6-36.

Authors

Mei Wu  1 , Akintunde Akinleye, Xiongpeng Zhu

Affiliation

  • 1 Department of Hematology, First Hospital of Quanzhou affiliated to Fujian Medical University, Quanzhou, 362000, China.

Abstract

Chronic lymphocytic leukemia (CLL) is a heterogeneous group of B-cell neoplasm. CLL is typically sensitive to a variety of cytotoxic agents, but relapse frequently occurs with conventional approaches. The treatment of CLL is evolving rapidly with the introduction of novel drugs, such as bendamustine, ofatumumab, lenalidomide, ibrutinib, idelalisib, veltuzumab, XmAb5574, navitoclax, dasatinib, alvespimycin, and TRU-016. This review summarizes the most current clinical experiences with these agents in the treatment of CLL.

PubMed Disclaimer

References

    1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11–30. doi: 10.3322/caac.21166. - DOI - PubMed
    1. Hernandez JA, Land KJ, McKenna RW. Leukemias, myeloma, and other lymphoreticular neoplasms. Cancer. 1995;75(1 Suppl):381–394. - PubMed
    1. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H, Hillmen P, Keating MJ, Montserrat E, Rai KR. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111(12):5446–5456. doi: 10.1182/blood-2007-06-093906. - DOI - PMC - PubMed
    1. Rai KR. The natural history of CLL and new prognostic markers. Clin Adv Hematol Oncol. 2008;6(5):4–5. quiz 10–12. - PubMed
    1. Binet JL, Auquier A, Dighiero G, Chastang C, Piguet H, Goasguen J, Vaugier G, Potron G, Colona P, Oberling F. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer. 1981;48(1):198–206. doi: 10.1002/1097-0142(19810701)48:1<198::AID-CNCR2820480131>3.0.CO;2-V. - DOI - PubMed

Publication types

MeSH terms

Full text links
BioMed Central full text link BioMed Central Free PMC article
Cite
Morty Proxy This is a proxified and sanitized view of the page, visit original site.